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The renin–angiotensin–aldosterone system (RAAS) plays 
an important role in the homeostasis of blood pressure 
regulation. Its role in the pathophysiology of hypertension 
is, however, complex. Over-activation of the RAAS in 
severe and accelerated phase hypertension is generally 
recognised but its role in drug-resistant hypertension less 
clear. This is one question being addressed by the British 
Hypertension Society PATHWAY Trial Programme (www.
bhsoc.org).
The interrelationships between the RAAS and the sym-
pathetic nervous system are also complex and extend from 
the central nervous system to the periphery, including 
post-ganglionic nerve endings, the adrenal gland and the 
kidney. It was therefore of considerable interest to note the 
impressive blood pressure reduction observed in early 
studies of renal denervation (RDN) in patients with appar-
ent drug-resistant hypertension and observe to what extent 
neurohumoral changes accompanied the falls in blood 
pressure.
By way of background, resistant hypertension is defined 
as blood pressure remaining above goal in spite of the con-
current use of three antihypertensive agents of different 
classes. Ideally one of these agents should be a diuretic, 
and all agents should be prescribed at optimal doses. Its 
true prevalence is unknown, but observational studies and 
clinical trials suggest that it is a common clinical problem. 
In an analysis of National Health and Nutrition Examination 
Survey (NHANES),1 of participants being treated for 
hypertension only 53% were controlled to a blood pressure 
<140/90 mmHg. In those with diabetes or chronic kidney 
disease the percentage controlled was considerably less. 
Similar figures (63%) for all treated patients have recently 
been reported by the Health Survey for England2 but, of 
course, many of the participants in these surveys were not 
receiving optimal treatment for their hypertension.
Resistant hypertension comprises a heterogeneous 
group of patients including those with undiagnosed sec-
ondary hypertension, inaccurate blood pressure measure-
ment, white coat hypertension and poor adherence with 
prescribed medication. In the author’s experience true 
resistant hypertension is uncommon. Thus, in the evalua-
tion of patients with apparent resistant hypertension, a 
comprehensive management algorithm should be applied 
which includes investigations to rule out secondary causes, 
confirmation of appropriate treatment (drugs and doses), 
including a trial of spironolactone, and formal assessment 
of drug compliance. This should include observed drug 
ingestion in the clinic followed by blood pressure monitor-
ing for up to 4 hours and 24 hour ambulatory blood pres-
sure monitoring thereafter. The post-dosing period of 
observation for 4 hours in the clinic is a precaution for 
cases where substantial falls in blood pressure occur in the 
hitherto non-compliant or poorly compliant patient. If the 
facility is available, urinary drug assays provide additional 
information on non-compliance.
Only after the diligent exclusion of the majority of 
patients referred with so-called resistant hypertension can 
true resistant hypertension be diagnosed with confidence.
In a series of 35 patients referred to a specialist clinic, 
all of whom claimed to be taking their medications as pre-
scribed, and in whom secondary causes for their hyperten-
sion had been eliminated and optimal treatment, including 
a trial of spironolactone, had been prescribed, following 
observed drug ingestion and 24-hour ambulatory blood 
pressure monitoring (ABPM), 60% achieved a blood pres-
sure of <140/90 mmHg and 80% <150/90 mmHg.3 The 
original series has now been extended to over 100 patients 
and the outcomes will shortly be available.
It is therefore manifest that poor drug compliance is the 
major contributing factor to apparent resistant hyperten-
sion, and without its systematic evaluation resistant hyper-
tension will be grossly over-diagnosed.
It is against this background that we can now look at 
the history of trials of RDN. In both Symplicity HTN-1 
(an uncontrolled study)4 and Symplicity HTN-2 (a non-
intervention controlled study),5 impressive reductions of 
clinic blood pressure (circa 30 mmHg systolic) were 
reported following RDN, and these reductions maintained 
during extended follow-up for up to 3 years. Other 
European Centres have reported similar impressive reduc-
tions in blood pressure in uncontrolled studies,6 and two 
meta-analyses have been published.7,8
There have been additional reports that the reductions 
in blood pressure have been accompanied by a fall in 
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plasma catecholamines,9 improvements in insulin sensitiv-
ity,10 reductions in plasma renin,11 (although this has not 
been a consistent finding9) and regression of left ventricu-
lar hypertrophy.12
In general the technique has, however, been uncritically 
accepted and practised worldwide. Specialist centres, 
including the author’s, receive weekly referrals from prac-
tising physicians for consideration of RDN in apparent 
treatment-resistant hypertension.
Against the hype surrounding RDN there have been 
few words of caution.
None of the Symplicity studies screened patients com-
prehensively for non- or poor compliance. Only one in five 
had received a trial of spironolactone, which in our experi-
ence has been shown to produce falls in blood pressure 
almost as great as those seen with RDN.13
In Symplicity HTN 2, the reduction in blood pressure 
with ABPM following RDN was only 11/7 mmHg, a far 
smaller reduction than one would have anticipated from 
the clinic recordings. As Howard and colleagues have 
pointed out,14 in drug trials without randomisation or 
blinding, clinic blood pressure reductions are substantially 
greater than reductions in blood pressure as assessed by 
ABPM. However, with randomisation and blinding, reduc-
tions as measured in the clinic and by ABPM are remark-
ably similar. These authors predicted that this would be the 
case with the first randomised, controlled, sham-operated 
trial of RDN, Symplicity HTN 3, with an effect size nearer 
to 10mm Hg than 30 mmHg systolic pressure.
Interestingly Fadl Elmula and colleagues have reported, 
in a small series of patients undergoing RDN with treat-
ment-resistant hypertension after witnessed intake of med-
ication and ABPM, that no fall in either clinic or ABPM 
blood pressures followed RDN.15 In a subsequent paper 
the same authors report that, after excluding poor drug 
compliance, adjusting drug treatment was more effective 
than RDN in lowering blood pressure in true resistant 
hypertension.16
Whilst many have urged caution over the widespread 
and often uncritical application of RDN to suspected cases 
of resistant hypertension, the technique has been exten-
sively adopted by cardiologists and interventional radiolo-
gists in many countries, with a proliferation of device 
manufacturers entering an anticipated rapidly expanding 
and lucrative market.
Guidelines on the application of RDN for the treatment 
of resistant hypertension have been published by the 
British Hypertension Society17 and other organisations,18 
but the strict criteria recommended prior to qualification 
for RDN have, in international practice, almost certainly 
not been adopted.
In symplicity HTN-3 was prematurely stopped because 
the trial failed to meet its primary endpoint, the change in 
office systolic blood pressure from baseline to 6 months,19 
the difference in systolic pressure between the intervention 
arm and the sham-operated arm being only 2 mmHg systolic 
pressure. This was obviously a far less impressive outcome 
than many would have anticipated from the earlier observa-
tional and non-sham controlled trials. The authors, however, 
confirmed that the procedure was safe, with few complica-
tions – an outcome similar to other earlier trials of RDN.
It has previously been suggested that substantial reduc-
tions in blood pressure in previous RDN trials could have 
been explained by better adherence to drug therapy follow-
ing the procedure, during intensive follow-up under close 
observation by physicians.20 Without doubt, from our 
observations in patients with resistant hypertension, and 
from studies of urine drug concentrations, compliance with 
medications is a major problem in this group of patients. It 
is entirely possible that in the context of a formal trial, par-
ticularly when RDN is controlled by a group undergoing a 
sham procedure, that improved compliance with drug tak-
ing post procedure would be similar in the two groups.
The possibility, in Symplicity HTN-3, that RDN was 
ineffective in the trial, compared with sham operation, 
because of inadequacies in the denervation procedure is 
extremely unlikely. The technique is relatively simple, and 
those participating in the trial will have been appropriately 
trained in its conduct.
So what of the future?
The scientific background and the work leading up to 
RDN was sound, and the innovative work of Esler and col-
leagues commendable.21 The early trials of RDN in man 
certainly reawakened interest in the role of the sympathetic 
nervous system in the pathophysiology of hypertension in 
general and, more specifically, in resistant hypertension. 
Following Symplicity HTN-3, however, we need to take a 
big step backwards to re-evaluate RDN. The Joint UK 
Societies have recommended a moratorium on RDN until 
the Symplicity HTN-3 outcomes have been appropriately 
analysed and digested.22 The device companies are review-
ing the development and marketing of newer catheters for 
RDN. In my opinion we need a further trial with a larger 
number of subjects than that reported by Fadl Elmula, 
where inclusion is restricted to those who are found to be 
truly treatment resistant after evaluation following 
observed drug ingestion. Only when such a study has been 
conducted can we begin to establish the future role of RDN 
in treatment-resistant hypertension (Figure 1).
This whole episode in the history of hypertension man-
agement raises interesting issues, the first being the neces-
sity for properly controlled randomised clinical trials to be 
carried out prior to the widespread and uncritical uptake of 
RDN in clinical practice. This would be required for any 
new antihypertensive drug, so why would we not demand 
that similar stringent processes are adopted prior to the 
introduction of a novel blood pressure-lowering device? 
(This must certainly apply to other devices and proposed 
methods to treat resistant hypertension that are currently 
being developed.) The second is the recognition of the 
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enormous problem of poor compliance with drug therapy 
in hypertensive patients. The cost to health providers of 
poor compliance is substantial, not only from the wastage 
of drugs, but the need for more clinic visits, repeated 
investigations and the morbidity and mortality associated 
with uncontrolled blood pressure. Drug assays on urine 
samples are inexpensive and cost effective and expose 
poor compliance. They should be used routinely in the 
work-up of patients with resistant hypertension.
Further research is needed on the pathophysiology of 
true resistant hypertension, with particular reference to the 
role of the sympathetic nervous system, the involvement 
of the RAAS, and the real problems of volume overload in 
some patients. Again The PATHWAY programme may 
shed some light on this.
There may, ultimately, be a place for RDN where drug 
taking is problematic due to side effects or other causes of 
non-compliance, and further controlled trials in such sub-
groups would be mandatory.
The natural history of RDN mimics the teaching to 
many generations of British medical students, on new 
drugs, by the late Desmond Lawrence – unrivalled enthu-
siasm, followed by total rejection and then an ultimate 
place for use in a restricted number of patients.
Let us not forget that other interventional procedures in 
medicine, such as tonsillectomy and knee arthroscopy with 
washout, have ultimately been shown to be of little value 
when objectively evaluated.
On the basis of the evidence to date, I put the following 
question to both the physicians and their patients with 
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